Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

27.10.2025

14 Alzheimers Dement
1 Ann Neurol
2 Brain
4 Curr Alzheimer Res
1 Exp Neurol
21 J Alzheimers Dis
1 J Am Geriatr Soc
1 J Neurol
1 J Neuropsychol
2 Lancet Neurol
1 Memory
1 Nature
2 Neurobiol Aging
1 Neurobiol Dis
1 Neurochem Res
1 Neurology
1 Neurosci Lett
1 Neuroscience
1 PLoS Biol
2 PLoS One
2 Proc Natl Acad Sci U S A


    Alzheimers Dement

  1. BUCHANAN RA, Kramer AT, Calipari ES, Bowman AB, et al
    Differential impact of manganese on glutamate clearance, electroencephalography, and sleep in Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70821.
    >> Share


  2. Correction to "Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives".
    Alzheimers Dement. 2025;21:e70876.
    >> Share

  3. CHEN XQ, Zuo X, Mobley WC
    Tau pathology differs by sex in Alzheimer's disease in Down syndrome.
    Alzheimers Dement. 2025;21:e70838.
    >> Share

  4. BIEL D, Steward A, Dewenter A, Dehsarvi A, et al
    A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70783.
    >> Share

  5. KUKULL WA
    The National Alzheimer's Coordinating Center (NACC) 1999-2025: Personal history and recollections.
    Alzheimers Dement. 2025;21:e70836.
    >> Share

  6. DODGE HH, Chen L, Wu CY, Cutter G, et al
    Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method.
    Alzheimers Dement. 2025;21:e70787.
    >> Share

  7. CHAUNSALI L, Li J, Fleischel E, Prim CE, et al
    Degradation of perineuronal nets in hippocampal CA2 explains the loss of social cognition memory in Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70813.
    >> Share

  8. GOODHEART AE, Brazier TL, Ye R, Stancu P, et al
    Towards optimizing the diagnosis of Lewy body dementia: Lessons from the NACC.
    Alzheimers Dement. 2025;21:e70794.
    >> Share

  9. SATO K, Niimi Y, Ihara R, Iwata A, et al
    Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers.
    Alzheimers Dement. 2025;21:e70652.
    >> Share

  10. LIU FT, Li XY, Lu JY, Zuo CT, et al
    Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.
    Alzheimers Dement. 2025;21:e70823.
    >> Share

  11. KHACHATURIAN Z
    History of Alzheimer's Disease Research Centers: From inception in 1984 to evolution beyond 2025.
    Alzheimers Dement. 2025;21:e70778.
    >> Share

  12. BACHMANN D, Wybitul M, Buchmann A, Gericke C, et al
    Predicting cognitive decline with amyloid-PET, plasma p-tau217, Abeta42/40, and p-tau217/Abeta42 in a community-based cohort - relevance for clinical trial enrollment.
    Alzheimers Dement. 2025;21:e70802.
    >> Share

  13. GOODWIN GJ, Fonseca J, Mehrzad S, Cummings JL, et al
    Classification of AD and bvFTD using neuropsychological and neuropsychiatric variables: a machine learning study.
    Alzheimers Dement. 2025;21:e70782.
    >> Share

  14. LI W, Han Y, Wang P, Song Q, et al
    Entwined processes in Alzheimer's disease: Brain cellular senescence and Alzheimer's disease pathology.
    Alzheimers Dement. 2025;21:e70803.
    >> Share


    Ann Neurol

  15. PIURA YD, Satyadev N, Corriveau-Lecavalier N, Kuchenbecker LA, et al
    Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia.
    Ann Neurol. 2025;98:764-776.
    >> Share


    Brain

  16. ASBY DJ, Fisher RA, Jackson J, Love S, et al
    Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease.
    Brain. 2025 Oct 22:awaf394. doi: 10.1093.
    >> Share

  17. MORRIS LA, Suzuki H, Lee S, Jin Z, et al
    Apathy, effort-based decisions and brain integrity in Alzheimer's and Parkinson's diseases.
    Brain. 2025 Oct 17:awaf393. doi: 10.1093.
    >> Share


    Curr Alzheimer Res

  18. MOON SS, Boyas JF, Lee J
    Assessing Alzheimer's Disease Risk Among Latina/o/x Older Adults: A CART Analysis.
    Curr Alzheimer Res. 2025 Oct 21. doi: 10.2174/0115672050413808250930051731.
    >> Share

  19. HUSING T, Quante A
    Auditory Hallucinations as the First Symptom of Alzheimer s Disease - A Case Report.
    Curr Alzheimer Res. 2025 Oct 21. doi: 10.2174/0115672050421769250929051818.
    >> Share

  20. SAEED RB, Alkharouby RA, Niaz LA, Maddah RA, et al
    The Comparison Between Dietary Vitamin A Deficiency and the CRP Level in Alzheimer's Disease in Patients with Type 2 Diabetes: A Case-Control Study.
    Curr Alzheimer Res. 2025 Oct 17. doi: 10.2174/0115672050396361250730115305.
    >> Share

  21. ABD-ALKAREEM MA, Jasim RH, Mashaan AO, Suleiman AA, et al
    An In silico Multi-Omics Investigation of Alzheimer's Disease Linking Gene Dysregulation, Mutations, and Protein Networks to Core Pathologies.
    Curr Alzheimer Res. 2025 Oct 15. doi: 10.2174/0115672050410268250919050955.
    >> Share


    Exp Neurol

  22. VRBJAR N, Radosinska D, Radosinska J
    The involvement of Na,K-ATPase enzyme in the development of Alzheimer's disease.
    Exp Neurol. 2025 Oct 21:115526. doi: 10.1016/j.expneurol.2025.115526.
    >> Share


    J Alzheimers Dis

  23. BEN ZAKEN K, Mesfin S, Bloch N, Samson AO, et al
    Virtual screening of drugs against multiple targets of Alzheimer's disease.
    J Alzheimers Dis. 2025 Oct 23:13872877251387167. doi: 10.1177/13872877251387167.
    >> Share

  24. DRZYMALLA E, Avery C, Palta P, Reiner AP, et al
    Association between neutrophil to lymphocyte ratio and Alzheimer's disease in large biobank cohorts.
    J Alzheimers Dis. 2025 Oct 23:13872877251386813. doi: 10.1177/13872877251386813.
    >> Share

  25. SALEMME S, Chiari A, Zamboni G, Tondelli M, et al
    Deciphering the A-T+ enigma: Clinical relevance or diagnostic noise?
    J Alzheimers Dis. 2025;107:1404-1405.
    >> Share

  26. BOCCALINI C, Garibotto V
    Is early-phase amyloid PET ready for use as neurodegeneration marker?
    J Alzheimers Dis. 2025;107:1411-1414.
    >> Share

  27. JUNG J, Ko H, Kim H, Lee H, et al
    Exposure to ambient carbon monoxide and cognitive decrease in a memory clinic.
    J Alzheimers Dis. 2025;107:1637-1644.
    >> Share

  28. WALTERS ME, Small BJ, Andel R, Lerch O, et al
    Differential MRI atrophy profiles and incident dementia: A cross-national comparison.
    J Alzheimers Dis. 2025;107:1539-1554.
    >> Share

  29. SPEH A, Boada M, Jessen F, Visser PJ, et al
    Cardiovascular health and cognition in older adults: Variations across recruitment models and European countries in the MOPEAD project.
    J Alzheimers Dis. 2025;107:1530-1538.
    >> Share

  30. SAIDO TC, Iwata N
    The tale of donanemab: God is in the details.
    J Alzheimers Dis. 2025;107:1364-1373.
    >> Share

  31. HALE MR, Langhough R, Basche KE, Betthauser TJ, et al
    Linking silent pause locations in speech to amyloid and tau deposition in cognitively unimpaired individuals.
    J Alzheimers Dis. 2025;107:1481-1497.
    >> Share

  32. THO CHU TQ, Morimoto K, Kowa H
    Cognitive performance and blood biomarkers: Insights into their relationship and predicting high Amyloid Probability Score in cognitively impaired older adults.
    J Alzheimers Dis. 2025;107:1661-1673.
    >> Share

  33. CHAITHRA PM, Rakshith BS, Logesh S, Kanthesh BM, et al
    Nutraceuticals intervention in Alzheimer's disease: From farm to pharma.
    J Alzheimers Dis. 2025 Oct 17:13872877251385216. doi: 10.1177/13872877251385216.
    >> Share

  34. RUBENSTEIN E, Tewolde S, Michals A, Fortea J, et al
    Novel predictors of Alzheimer's disease in Down syndrome identified using machine learning.
    J Alzheimers Dis. 2025 Oct 17:13872877251385423. doi: 10.1177/13872877251385423.
    >> Share

  35. YE H, Zhuang C, Jin Z, Hu Y, et al
    VEGFB is a potential therapeutic target for Alzheimer's disease: Insights from integrative multi-omics analysis.
    J Alzheimers Dis. 2025 Oct 17:13872877251385244. doi: 10.1177/13872877251385244.
    >> Share

  36. BI X, Xiao X, Zhou L, Liu Q, et al
    Exploring multitarget molecular mechanisms of cannabidiol in Alzheimer's disease treatment using molecular simulations and modeling.
    J Alzheimers Dis. 2025 Oct 17:13872877251386440. doi: 10.1177/13872877251386440.
    >> Share

  37. PEREZ-NAVARRO LM, Lopez-Alvarenga JC
    A molecular renaissance in Alzheimer's disease research: The rise of systems biology and spatial omics.
    J Alzheimers Dis. 2025 Oct 17:13872877251387169. doi: 10.1177/13872877251387169.
    >> Share

  38. GABRIEL V, Chabran E, Sourty M, Cretin B, et al
    Salience and frontoparietal network impairments across disease stages in dementia with Lewy bodies: A comparative functional MRI study with Alzheimer's disease.
    J Alzheimers Dis. 2025 Oct 17:13872877251386844. doi: 10.1177/13872877251386844.
    >> Share

  39. AVENEAU C, Lamy E, Grassin-Delyle S, Sanchez-Ortiz M, et al
    Cerebrospinal fluid acetylcholine is not a reliable diagnostic marker for Alzheimer's disease and dementia with Lewy bodies.
    J Alzheimers Dis. 2025 Oct 22:13872877251387159. doi: 10.1177/13872877251387159.
    >> Share

  40. SOSA PEREZ S, Urrutia Amable N, Viada Gonzalez CE, Lorenzo-Luaces P, et al
    NeuroEPO plus (NeuralCIM((R))) in Alzheimer's disease: Post-trial observational follow-up study.
    J Alzheimers Dis. 2025 Oct 22:13872877251386885. doi: 10.1177/13872877251386885.
    >> Share

  41. LI C, Feng L, Li M, Dai C, et al
    Research progress on the regulation of Nrf2/HO-1 signaling pathway by traditional Chinese medicine in the treatment of Alzheimer's disease.
    J Alzheimers Dis. 2025 Oct 22:13872877251389011. doi: 10.1177/13872877251389011.
    >> Share

  42. LEE J, Kim YJ, Kim W, Cho S, et al
    Cumulative burden of lifestyle risk factors on Alzheimer's disease in older Korean adults: A nationwide retrospective cohort study.
    J Alzheimers Dis. 2025 Oct 22:13872877251386889. doi: 10.1177/13872877251386889.
    >> Share

  43. WANG XY, Jia YJ, Zhang J, Chen JF, et al
    Therapeutic potential of 40 Hz flickering light stimulation in Alzheimer's disease: Mechanisms, evidence, and controversies.
    J Alzheimers Dis. 2025 Oct 22:13872877251388664. doi: 10.1177/13872877251388664.
    >> Share


    J Am Geriatr Soc

  44. SHAH KM, Jain B, Komanduri A, Kuchibhotla S, et al
    Characterization of National Institute on Aging-Funded Clinical Trials for Alzheimer's Disease.
    J Am Geriatr Soc. 2025 Oct 22. doi: 10.1111/jgs.70185.
    >> Share


    J Neurol

  45. GUO X, Yue R, Cui Z, Wang S, et al
    Advances of therapeutic strategies for Alzheimer's disease.
    J Neurol. 2025;272:705.
    >> Share


    J Neuropsychol

  46. DI PALMA V, Fadda L, Massimi V, Leonardi C, et al
    Delayed recall from the primacy portion of a story predicts conversion of patients with mild cognitive impairment to Alzheimer's disease.
    J Neuropsychol. 2025 Oct 21. doi: 10.1111/jnp.70017.
    >> Share


    Lancet Neurol

  47. IWATSUBO T
    Neuropathology of Alzheimer's disease after anti-amyloid beta antibody treatment.
    Lancet Neurol. 2025;24:897-899.
    >> Share

  48. BOON BDC, Piura YD, Moloney CM, Chalk JL, et al
    Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
    Lancet Neurol. 2025;24:931-944.
    >> Share


    Memory

  49. MOLTRASIO J, Rubinstein W
    The soundtrack of memory: the effect of music on emotional memory in Alzheimer's disease and older adults.
    Memory. 2025 Oct 17:1-15. doi: 10.1080/09658211.2025.2573267.
    >> Share


    Nature

  50. KAVANAGH K
    Blood tests are now approved for Alzheimer's: how accurate are they?
    Nature. 2025 Oct 17. doi: 10.1038/d41586-025-03394.
    >> Share


    Neurobiol Aging

  51. GUO L, Zhou Y, Lu H, Fung HH, et al
    The moderating effect of cognitive reserve on the association between neuroimaging biomarkers and cognition: A systematic review.
    Neurobiol Aging. 2025;156:10-29.
    >> Share

  52. NAKAMURA R, Okada M, Takahashi A, Hayashi Y, et al
    A synthetic nonapeptide, JAL-TA9, inhibits neuronal cytotoxicity caused by Abeta25-35 aggregation with proteolytic activity.
    Neurobiol Aging. 2025;156:123-132.
    >> Share


    Neurobiol Dis

  53. LIU A, Do Carmo S, Antel JP, Kuhlmann T, et al
    White matter degeneration precedes tau aggregation in rats with Alzheimer's-like tauopathy.
    Neurobiol Dis. 2025;216:107149.
    >> Share


    Neurochem Res

  54. HOVEIZI E, Bijavi G, Parsa H
    Advancing Cell Therapy to Enhance Passive Avoidance Memory: Integrative Approaches Combining Neural-Like Cells and Rosmarinic Acid Through Behavioral, Molecular, and Histological Analyses.
    Neurochem Res. 2025;50:334.
    >> Share


    Neurology

  55. LOPEZ-MARTOS D, Suarez-Calvet M, Mila-Aloma M, Gispert JD, et al
    Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.
    Neurology. 2025;105:e214308.
    >> Share


    Neurosci Lett

  56. YI JH
    From stress to Alzheimer's: A circuit-based framework for prefrontal cognitive dysfunction.
    Neurosci Lett. 2025 Oct 18:138424. doi: 10.1016/j.neulet.2025.138424.
    >> Share


    Neuroscience

  57. DAS R, Chatterjee A, Roy S
    An interpretable Bayesian framework for Alzheimer's disease prediction with uncertainty quantification.
    Neuroscience. 2025 Oct 15:S0306-4522(25)01013.
    >> Share


    PLoS Biol

  58. CHENG YH, Ho MS
    Disease-associated microglia in neurodegenerative diseases: Friend or foe?
    PLoS Biol. 2025;23:e3003426.
    >> Share


    PLoS One


  59. Editorial Note: Complete Phenotypic Recovery of an Alzheimer's Disease Model by a Quinone-Tryptophan Hybrid Aggregation Inhibitor.
    PLoS One. 2025;20:e0335097.
    >> Share

  60. LIU Y, Wang J, Wu P, Tang F, et al
    Mitochondrial dysfunction-related metabolite methylmalonic acid is associated with decreased cognitive performance.
    PLoS One. 2025;20:e0332987.
    >> Share


    Proc Natl Acad Sci U S A

  61. ZHAO R, Sophanpanichkul P, Chadarevian JP, Ding Y, et al
    Amyloid precursor protein and C99 are subunits in human microglial Hv1 channels that enhance current and inflammatory mediator release.
    Proc Natl Acad Sci U S A. 2025;122:e2509903122.
    >> Share

  62. STANTON AE, Bubnys A, Agbas E, James B, et al
    Engineered 3D immuno-glial-neurovascular human miBrain model.
    Proc Natl Acad Sci U S A. 2025;122:e2511596122.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016